Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases
Jul 4, 2025
Schlechter, et al.
Filter by
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 19
- Oct 23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.
Coward, et al.
Zalifrelimab (CTLA-4 Antagonist)
PLOS
Apr 4, 2018
Toxicological and Pharmacological Assessment of AGEN1884, a Novel Human IgG1 anti-CTLA-4 Antibody.
Gombos, et al.
Zalifrelimab (CTLA-4 Antagonist)
Journal for ImmunoTherapy of Cancer
Aug 8, 2019
Angiosarcoma Patients Treated with Immune Checkpoint Inhibitors: A Case Series of Seven Patients from a Single Institution.
Florou, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials.
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822).
Perez, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Pseudoprogression (PSP) Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer.
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
VISION
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
Driving T cell Dysfunction in Vitro for Rational Immunotherapy Design.
Joyce, et al.
VISION
AI Powered Drug Discovery and Manufacturing (AIDM)
Feb 27
- Feb 28, 2020
Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors.
Pabla, et al.
VISION
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro.
Pabla, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Jan 15, 1991
Separation and Characterization of Saponins With Adjuvant Activity From Quillaja Saponaria Molina Cortex.
Kensil, CR.